AIM-HI Accelerator Fund shared a post on LinkedIn:
“AIM-HI Accelerator Fund is proud to share major clinical progress from our portfolio company, Privo Technologies.
Privo announced new results from its ongoing Phase 2/3 trial evaluating PRV111, a first-in-class, non-surgical therapy for early-stage non-invasive oral cancer and high-grade dysplasias.
Key outcomes announced today include:
- 92 percent complete response rate (11 of 12 patients)
- All patients avoided surgery following treatment
- No recurrences observed to date, with responses maintained up to 12 months
- Strong tolerability with negligible systemic exposure
These results underscore the potential of PRV111 to offer a meaningful, non-surgical alternative for patients who currently face repeated resections, functional impairments, and significant quality-of-life challenges.
We congratulate Privo Technologies on this important milestone and look forward to supporting their continued progress as they advance toward registrational studies.”
More posts featuring AIM-HI Accelerator Fund.